Observes people with ME/CFS or long COVID taking low-dose rapamycin
Tracks symptoms and blood markers in adults with ME/CFS or long COVID.
Plain-language title generated from the registry record
Registry title: Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
Key facts
- Where
- Incline Village, Palo Alto, Rochester, Salt Lake City, and Seattle, United StatesSee the 5 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06257420, who can take part
Where in United States
- Sierra Internal MedicineIncline Village, United StatesNo longer taking part
- Center For Complex DiseasesPalo Alto, United StatesNo longer taking part
- The Mayo ClinicRochester, United StatesNo longer taking part
- Bateman Horne CenterSalt Lake City, United StatesNo longer taking part
- Center For Complex DiseasesSeattle, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Simmaron Research Inc.
- Trial code
- NCT06257420
- Record updated
- 18 May 2026
- Original description
The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are:Read full original descriptionShow less
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are:
* Does rapamycin reduce the overall symptom burden in this patient population and does it improve the quality of life? * Does rapamycin change mTOR driven autophagy deficits observed in a subset of patients?
Participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. Study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy function.
Inclusion: Diagnosis of ME/CFS that meets the Institute of Medicine (IOM) criteria; Diagnosis of Long-COVID (PASC clinical criteria).
Exclusion: No diagnosis of ME/CFS or Long-COVID.